exelon
novartis new zealand ltd - rivastigmine tartrate 9.6mg equivalent to 6 mg rivastigmine; - capsule - 6 mg - active: rivastigmine tartrate 9.6mg equivalent to 6 mg rivastigmine excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.
exelon
novartis new zealand ltd - rivastigmine tartrate 3.2 mg/ml equivalent to 2 mg/ml rivastigmine base; - oral solution - 2 mg/ml - active: rivastigmine tartrate 3.2 mg/ml equivalent to 2 mg/ml rivastigmine base excipient: citric acid monohydrate purified water quinoline yellow sodium benzoate sodium citrate dihydrate - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.
exelon patch 10
novartis new zealand ltd - rivastigmine 18mg; ; - transdermal patch - 9.5 mg/24h - active: rivastigmine 18mg excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 10 cm square release liner 20.25 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.
exelon patch 15
novartis new zealand ltd - rivastigmine 27mg; ; - transdermal patch - 13.3 mg/24h - active: rivastigmine 27mg excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 15 cm square release liner 30.375 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.
exelon patch 5
novartis new zealand ltd - rivastigmine 9mg; ; - transdermal patch - 4.6 mg/24h - active: rivastigmine 9mg excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 5 cm square release liner 10.125 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.
losartan hctad
boucher & muir (new zealand) limited t/a bnm group - hydrochlorothiazide 12.5mg; losartan potassium 50mg - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg losartan potassium 50mg excipient: hypromellose lactose monohydrate macrogol 4000 magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc quinoline yellow titanium dioxide - losartan hctad is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate.
nizoral
janssen-cilag (new zealand) ltd - ketoconazole 200mg - tablet - 200 mg - active: ketoconazole 200mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone
motilium
j-c health care ltd - domperidone - tablets - domperidone 10 mg - domperidone - domperidone - motilium is indicated for the relief of the symptoms of nausea and vomiting.
tambocor 50 mg tablets
megapharm ltd - flecainide acetate - tablets - flecainide acetate 50 mg - flecainide - flecainide - serious sustained life threatening supraventricular arrhythmias that have not responded to other drugs. paroxysmal atrial fibrillation and atrial flutter
tambocor 100 mg tablets
megapharm ltd - flecainide acetate - tablets - flecainide acetate 100 mg - flecainide - flecainide - serious sustained life threatening ventricular arrhytmias that have not responsed to other drugs. paroxymal atrial flutter.